Effect of tibolone on glucose and lipid metabolism in postmenopausal women

The effect of tibolone, a new therapeutic agent for menopause, on glucose and lipid metabolism was investigated in 11 healthy postmenopausal women. At baseline and after 3 months of tibolone administration (2.5 mg/day), glucose metabolism was evaluated in each subject using both an oral glucose tole...

Full description

Saved in:
Bibliographic Details
Published in:The journal of clinical endocrinology and metabolism 1997, Vol.82 (1), p.251-253
Main Authors: CAGNACCI, A, MALLUS, E, TUVERI, F, CIRILLO, R, SETTENERI, A. M, MELIS, G. B
Format: Article
Language:English
Subjects:
Anabolic Agents
Apolipoproteins A - metabolism
Apolipoproteins B - blood
Biological and medical sciences
Blood Glucose - metabolism
Body Mass Index
Cholesterol - blood
Cholesterol, HDL - blood
Female
General and cellular metabolism. Vitamins
Glucose Tolerance Test
Humans
Insulin - blood
Lipids - blood
Medical sciences
Middle Aged
Norpregnenes - adverse effects
Norpregnenes - therapeutic use
Pharmacology. Drug treatments
Postmenopause - blood
Triglycerides - blood
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The effect of tibolone, a new therapeutic agent for menopause, on glucose and lipid metabolism was investigated in 11 healthy postmenopausal women. At baseline and after 3 months of tibolone administration (2.5 mg/day), glucose metabolism was evaluated in each subject using both an oral glucose tolerance test (75 g) and the minimal model method of a frequently sampled intravenous glucose tolerance test. Frequently sampled intravenous glucose tolerance test allows the calculation of insulin sensitivity and peripheral glucose use independent of insulin. High-density lipoprotein-cholesterol, total cholesterol, apoprotein-A, and apoprotein-B measured in fasting conditions were not modified by tibolone, whereas triglycerides were reduced significantly (P < 0.01). Fasting levels of glucose were reduced significantly (P < 0.025), whereas those of insulin, C-peptide, and the C-peptide/insulin ratio were not modified. Glucose, insulin, C-peptide, and the C-peptide/insulin ratio responses to oral or iv glucose were not modified. Insulin sensitivity was inversely correlated to body mass index, and independent on that body mass index was significantly enhanced (P < 0.01). Glucose utilization independent of insulin was not modified. The present data indicate that tibolone does not negatively influence glucose metabolism and may indeed improve both the peripheral tissue sensitivity to insulin and the lipid profile.
ISSN:0021-972X
1945-7197
DOI:10.1210/jc.82.1.251